RKDANasdaqCrude Petroleum & Natural GasFiscal year ends December 31
Arcadia Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.14−0.02 (-12.01%)
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
Arcadia Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $1.44M | $1.10M | $901.00K | $1.30M | $1.46M | $1.20M | $1.18M | $1.54M | $1.31M | $987.00K | $770.00K | $1.30M | 100.0% | -0.8% |
| License | – | – | – | – | – | – | $7.00K | $0 | $0 | – | $7.00K | $0 | – | – |
| Royalty | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Arcadia Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.